Your browser doesn't support javascript.
loading
Novel myostatin-specific antibody enhances muscle strength in muscle disease models.
Muramatsu, Hiroyasu; Kuramochi, Taichi; Katada, Hitoshi; Ueyama, Atsunori; Ruike, Yoshinao; Ohmine, Ken; Shida-Kawazoe, Meiri; Miyano-Nishizawa, Rie; Shimizu, Yuichiro; Okuda, Momoko; Hori, Yuji; Hayashi, Madoka; Haraya, Kenta; Ban, Nobuhiro; Nonaka, Tatsuya; Honda, Masaki; Kitamura, Hidetomo; Hattori, Kunihiro; Kitazawa, Takehisa; Igawa, Tomoyuki; Kawabe, Yoshiki; Nezu, Junichi.
Affiliation
  • Muramatsu H; Research Division, Chugai Pharmaceutical Co., Ltd., Tokyo, 103-8324, Japan.
  • Kuramochi T; Chugai Pharmabody Research Pte. Ltd., 3 Biopolis Drive, #07-11 to 16, Synapse, Singapore, 138623, Singapore.
  • Katada H; Research Division, Chugai Pharmaceutical Co., Ltd., Tokyo, 103-8324, Japan.
  • Ueyama A; Research Division, Chugai Pharmaceutical Co., Ltd., Tokyo, 103-8324, Japan.
  • Ruike Y; Research Division, Chugai Pharmaceutical Co., Ltd., Tokyo, 103-8324, Japan.
  • Ohmine K; Research Division, Chugai Pharmaceutical Co., Ltd., Tokyo, 103-8324, Japan.
  • Shida-Kawazoe M; Research Division, Chugai Pharmaceutical Co., Ltd., Tokyo, 103-8324, Japan.
  • Miyano-Nishizawa R; Research Division, Chugai Pharmaceutical Co., Ltd., Tokyo, 103-8324, Japan.
  • Shimizu Y; Research Division, Chugai Pharmaceutical Co., Ltd., Tokyo, 103-8324, Japan.
  • Okuda M; Chugai Pharmabody Research Pte. Ltd., 3 Biopolis Drive, #07-11 to 16, Synapse, Singapore, 138623, Singapore.
  • Hori Y; Research Division, Chugai Pharmaceutical Co., Ltd., Tokyo, 103-8324, Japan.
  • Hayashi M; Research Division, Chugai Pharmaceutical Co., Ltd., Tokyo, 103-8324, Japan.
  • Haraya K; Research Division, Chugai Pharmaceutical Co., Ltd., Tokyo, 103-8324, Japan.
  • Ban N; Research Division, Chugai Pharmaceutical Co., Ltd., Tokyo, 103-8324, Japan.
  • Nonaka T; Research Division, Chugai Pharmaceutical Co., Ltd., Tokyo, 103-8324, Japan.
  • Honda M; Research Division, Chugai Pharmaceutical Co., Ltd., Tokyo, 103-8324, Japan.
  • Kitamura H; Research Division, Chugai Pharmaceutical Co., Ltd., Tokyo, 103-8324, Japan.
  • Hattori K; Research Division, Chugai Pharmaceutical Co., Ltd., Tokyo, 103-8324, Japan.
  • Kitazawa T; Research Division, Chugai Pharmaceutical Co., Ltd., Tokyo, 103-8324, Japan.
  • Igawa T; Chugai Pharmabody Research Pte. Ltd., 3 Biopolis Drive, #07-11 to 16, Synapse, Singapore, 138623, Singapore.
  • Kawabe Y; Research Division, Chugai Pharmaceutical Co., Ltd., Tokyo, 103-8324, Japan.
  • Nezu J; Research Division, Chugai Pharmaceutical Co., Ltd., Tokyo, 103-8324, Japan. nezujyn@chugai-pharm.co.jp.
Sci Rep ; 11(1): 2160, 2021 01 25.
Article in En | MEDLINE | ID: mdl-33495503
Subject(s)
Fulltext
Add to My VHL
Print
XML
PubMed Links
Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Muscle Strength / Myostatin / Antibodies, Monoclonal / Muscular Diseases Type of study: Prognostic_studies Limits: Animals Language: En Journal: Sci Rep Year: 2021 Document type: Article Affiliation country: Japan
Fulltext
Add to My VHL
Print
XML
PubMed Links
Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Muscle Strength / Myostatin / Antibodies, Monoclonal / Muscular Diseases Type of study: Prognostic_studies Limits: Animals Language: En Journal: Sci Rep Year: 2021 Document type: Article Affiliation country: Japan